Form 4: Sensei Biotherapeutics Director and 10% Owner James Peyer Reports Grant of Stock Options

Sensei Biotherapeutics, Inc. Director and 10% owner James Peyer reported the indirect acquisition of 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Summary

• James Peyer, a Director and 10% Owner of Sensei Biotherapeutics, Inc. (SNSE), reported the acquisition of 19,000 stock options.
• The transaction date for the option grant was May 21, 2025.
• Each stock option has an exercise price of $0.3202.
• The options are for 19,000 shares of Sensei Biotherapeutics' Common Stock.
• The options vest in 12 equal monthly installments over a one-year period, becoming fully vested by May 21, 2026, or earlier on the date of the Company's next annual stockholder meeting, subject to Mr. Peyer's continuous service.
• The options are indirectly held by Cambrian Biopharma Inc., where Mr. Peyer serves as Chief Executive Officer and may direct their voting and disposition, although he disclaims beneficial ownership.

Sentiment

Score: 6

Explanation: The grant of stock options to a director and 10% owner is a standard practice for aligning management and shareholder interests, indicating continued commitment. However, it is a routine disclosure and does not inherently signal significant positive or negative operational news.

Positives

• The grant of 19,000 stock options to a Director and 10% owner, James Peyer, aligns his interests with the long-term shareholder value of Sensei Biotherapeutics.
• The vesting schedule encourages continuous service and commitment from Mr. Peyer to the company's performance over the next year.

Risks

• The value of the granted stock options is contingent on Sensei Biotherapeutics' stock price exceeding the exercise price of $0.3202 per share.
• The vesting of the options is subject to Mr. Peyer's continuous service with the Issuer, meaning unvested options could be forfeited if his service terminates prematurely.

Future Outlook

This Form 4 filing reports a specific insider transaction and does not provide a general future outlook for the company. The vesting schedule of the options indicates an expectation of continued service from the reporting person.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context. Stock option grants are a common form of equity compensation in the biotechnology and pharmaceutical sectors, used to incentivize and retain key personnel, including directors and significant shareholders, by aligning their financial interests with the company's long-term performance.

Related Party Transactions

• The stock options are indirectly held by Cambrian Biopharma Inc., a Delaware corporation, where the reporting person, James Peyer, serves as Chief Executive Officer.
• Mr. Peyer, in his capacity as CEO of Cambrian, may direct the voting and disposition of these options, subject to Cambrian's Board of Directors' approval, though he disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: The grant of options to a director and significant shareholder aims to align their interests with long-term shareholder value, potentially leading to more focused efforts on company performance.
• Management/Employees: This transaction is a form of equity compensation, which is a common incentive for key personnel.

Next Steps

• The granted stock options will vest in monthly installments over the next year, with full vesting by May 21, 2026, or at the next annual stockholder meeting.
• The reporting person may exercise the vested options to acquire common stock at the exercise price of $0.3202 per share.

Key Dates

Recommendation

Keywords

Sensei Biotherapeutics, SNSE, James Peyer, Stock Option, Form 4, Insider Transaction, Director, 10% Owner, Equity Compensation, Cambrian Biopharma